Clinical trial · Observational
Venous Thromboembolism in Advanced Lung Cancer
Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism (VTE) in Chinese Advanced Stage Lung Cancer
NCT03581708CI-TRIAL-00033697RIVALunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observatory clinical study, aiming to establish and validate venous thromboembolism risk model in Chinese advanced non-small cell lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| lung cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- advanced lung cancer
- description
- Patients diagnosed with advanced lung cancer
- interventionNames
- Other: lung cancer
Primary outcomes (1)
- measure
- VTE incidence risk evaluation
- timeFrame
- 12 months
- description
- Real world VTE incidence risk evaluation in advanced lung cancer. Establish and validate VTE risk predictive model in Chinese advanced lung cancer.
Secondary outcomes (2)
- measure
- VTE incidence
- timeFrame
- 12 months
- description
- VTE incidence in advanced lung cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years at the time of screening. * Eastern Cooperative Oncology Group performance status of ≤ 2. * Written informed consent obtained from the patient. * Histologically and cytologically documented Stage 3B-4 lung cancer (according to Version 8 of the International Association for the Study of Lung Cancer Staging system). * Patients with stage 1 to 3, who undergo radical therapy with disease free survival (DFS) \>12 months. * Willingness and ability to comply with scheduled visits and other study procedures. Exclusion Criteria: * History of another primary malignancy except for malignancy treated with curative intent with known active disease ≥ 5 years before date of the informed consent. * Without signed informed consent. * Unwillingness or inability to comply with scheduled visits or other study procedures. * Previously diagnosed with VTE before signing informed consent.
References
Publications (8)
- BACKGROUNDKhorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23. PMID 18216292
- RESULTBlom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22. doi: 10.1001/jama.293.6.715. PMID 15701913
- RESULTTesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med. 2007 Sep;13(5):362-7. doi: 10.1097/MCP.0b013e328209413c. PMID 17940477
- RESULTLevitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91. doi: 10.1097/00005792-199909000-00001. PMID 10499070
- RESULTThodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002 Jun;87(6):1076-7. No abstract available. PMID 12083490
- RESULTStein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006 Jan;119(1):60-8. doi: 10.1016/j.amjmed.2005.06.058. PMID 16431186
- RESULTChew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008 Apr;6(4):601-8. doi: 10.1111/j.1538-7836.2008.02908.x. Epub 2008 Jan 17. PMID 18208538
- RESULTWang Z, Yan HH, Yang JJ, Wang BC, Chen HJ, Zhou Q, Xu CR, Jiang BY, Wu YL. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer. 2015 Mar;23(3):635-41. doi: 10.1007/s00520-014-2405-y. Epub 2014 Aug 27.